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Case presentation
A 44-year-old black woman with incomplete exstrophy of the urinary
bladder has been followed for renal insufficiency and radiopaque calculi
over the last 5 years. Twenty-two years ago, the right kidney was
removed and the left ureter implanted into an ileal conduit because of
severe infection and obstruction; the serum creatinine then was 1.3
mg/dl. During the ensuing 8 years, serum creatinine fluctuated between
1.4 mg/dl and 1.8 mg/dl, serum calcium between 8.9 and 10.2 mg/dl, and
serum phosphorus between 3.3 and 4.5 mg/dl. The 24-hour urine
calcium and phosphorus levels ranged between 30 and 150 mg/dl and
350 and 680 mg/day respectively. Fourteen years ago, a left nephroli-
thotomy was performed; postoperative serum creatinine levels were 1.6
and 1.7 mg/dl. Bacteriuria has been present consistently and, a couple
of times yearly, she has required systemic antibiotics for overt urinary
tract infections. No urosepsis has been documented.
The serum creatinine concentration averaged 1.8 to 1.9 ten years ago.
An ileal "loopogram" at that time revealed three 2.5 cm opaque calculi
in the left lower pole calyces, with a dilated middle calyx and reflux of
contrast material. Serum chloride (108 to 111 mEq/liter), carbon dioxide
(18 mEq/liter), and blood pH (7.34) 7 years ago were consistent with
mild hyperchioremic metabolic acidosis. The 3 calculi appeared denser
6 years ago, although their size was unchanged. The serum creatinine
gradually rose to 2.2 mg/dl; the serum calcium (9.6 to 10.0 mg/dl) and
phosphorus (3.2 mg/dl) remained within normal limits. In a typical
24-hour urine sample, volume was 2000 ml; creatinine, 1.37 g; oxalate,
40 mg; phosphorus, 560 mg; sodium, 178 mEq; uric acid, 512 mg;
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calcium, 102 mg; and citrate, 373 mg. No gross hematuria was noted,
and no gravel was passed. She took trimethoprim-sulfamethoxazole
between 5 and 8 years ago.
Five years ago, her blood pressure was 132/72 mm Hg. She weighed
80.5 kg and had a normal cardiopulmonary examination. The ileal
cutaneous fistula was clean and healthy. There was no tenderness in the
costovertebral angles or in her abdomen. The extremities were free of
edema. The urinary specific gravity was 1.009. Dipstick testing of the
urine revealed: pH, 6; no glucose or ketone; I + proteinuria, and a trace
of blood. Occasional bacteria, 2 red blood cells, and 10 to 15 white
blood cells/high-power field were apparent on microscopic examination
of the urine sediment. Crystals and casts were absent. The hemoglobin
was 14.1 g/dl and the hematocrit was 40,8%.
At that time, the working diagnosis was mild renal insufficiency due
to reflux nephropathy. The problem was complicated by chronic
bacteriuria and pelvocalyceal calculi, presumably containing phos-
phate. Lithotripsy, attempted twice, was only partially successful in
breaking up the calyceal stones. On analysis, one calculus consisted of
58% struvite (Mg NH4 P04), 32% carbonate apatite, 2% NH4 acid urate,
and 8% blood. She was treated with calcium carbonate, and small doses
of aluminum hydroxide if she became hypercalciuric, to prevent phos-
phate retention. Fluids were prescribed to increase urine volume to
greater than 2.5 liters/day; this goal was easily achieved. Initially her
diet was not modified. Two years ago, sodium bicarbonate was given to
maintain the serum bicarbonate over 16 mEq/liter. Furosemide soon
was added to sustain a normal blood pressure. Between one and five
years ago, her urine phosphorus ranged between 101 and 412 mg/day
(mean SE, 233 32 mg); the mean SE for urine calcium was 116
16 mg/day. Urine phosphorus-to-creatinine ratio fell from 0.41 to 0.19
0.030. The serum phosphorus ranged from 2.7 to 4.3 mg/dl (mean
SE, 3.6 0.2). Serum creatinine averaged 2.2 0.1 mg/dl. Serum
calcium averaged 9.8 0.4 mg/dl. The patient has remained normoten-
sive and asymptomatic from overt infection, renal colic, or signs of
complications from azotemia.
Discussion
DR. KAI LAu (Director of Nephrology, Michael Reese Hos-
pital, and Associate Professor of Medicine, University of
Chicago, Chicago, Illinois): After the process of renal disease is
initiated, limited therapeutic modalities are available to nephrol-
ogists for reversing and/or stabilizing the disease course. For
this reason we have learned to be vigorous and aggressive in
controlling hypertension. We deliberately avoid nephrotoxic
insults like unnecessary exposure to contrast materials, amino-
glycosides, phenacetin-containing analgesics and, lately, non-
steroidal antiinflammatory agents. We attempt to correct
reversible factors such as infection, obstruction, and renal
hemodynamic compromise, and we counsel against the contin-
ued use of heroin or sensitizing antibiotics. Unfortunately, the
clinical course of an established disease is relentlessly downhill.
Therefore the concept that manipulation of dietary factors like
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sodium, protein, calories, and lipids might halt progressive
renal disease is exciting.
In the last 8 years, three Forum discussants have reviewed
the role of dietary protein [1—31. Although my focus is on
phosphate, some reference to protein becomes inevitable and
perhaps even useful. I would like to raise a testable hypothesis
that I hope will stimulate more research on this clinical prob-
lem. This hypothesis, known as the precipitation-calcification
hypothesis, proposes that phosphate absorbed in excess of
residual nephron excretory capacity produces precipitation and
deposition of calcium phosphate microcrystals in the tubular
lumen, peritubular space, capillaries, and interstitium and is
thus responsible for progressive functional deterioration in
chronic renal failure. In other words, an undue phosphate
burden is deleterious to the anatomic and functional integrity of
residual nephrons. Pathophysiologic alterations and eventually
pathologic destructions ensue, further compromising renal
function and setting up a vicious cycle by precipitating more
phosphate and calcium in the renal parenchyma.
Despite a number of studies on the presumed benefits of a
low-phosphate diet on renal function (Table 1), it is still unclear
whether reduced dietary phosphorus per se is solely responsi-
ble.
To assess the separate roles of phosphate and protein in the
progession of renal disease, it is logical to turn first to studies in
humans with renal disease. Unfortunately, none of the pub-
lished studies provides such insights. Each published study
contains the following confounding variables that make it
impossible to identify the unique effects of protein and phos-
phate restriction. (1) Protein restriction and phosphate restric-
tion were simultaneous. (2) Study periods were too short to
observe an effect. (3) The number of patients studied was small.
(4) Glomerular filtration rate (GFR) was rarely measured.
Instead, serum creatinine was usually employed to evaluate
renal function. Given that creatinine production fell in many
such patients, the stability in serum creatinine over time might
not have been a reflection of stable glomerular function. (5) In
some studies, patients included in one study might have been
included in a later study. (6) Contemporaneous, well-matched
controls were rarely used; historic controls were more com-
monly employed. (7) The possible role of more intensive
medical care related to more frequent visits to physicians was
not excluded. Although the results were negative, one of the
earliest studies [4] amply illustrates the problems created by
these confounding variables. Given these serious flaws in
experimental design, we are unable to draw any conclusion
about the independent effects of phosphate restriction on renal
function from clinical trials.
To validate this opinion, I shall first review the principal
studies in this area. Maschio and coworkers examined the
effects of a 650 mg/day phosphorus diet in 3 groups of patients
with mild-to-moderate renal insufficiency, and compared these
effects with those of a 900 mg intake before the diet and with
those of 30 different patients on an ad-libitum phosphorus diet
in the same patients [5, 61. The reciprocal of serum creatinine
against time was stable in the patients with an initial serum
creatinine of 2.2 mg/dl, it progressed minimally in those with a
creatinine of 4.2 mg/dl, and it declined significantly less in those
with a creatinine of 6.1 mg/dl relative to the control. There are
several problems in their study design, however.
First, their controls were derived from a different population,
and the subjects were followed according to a different proto-
col. Second, the study was brief, especially for those with a
starting serum creatinine of less than 2.5 mg'dl. In the group
with a serum creatinine of 6.1 mg/dl, for example, 40% experi-
enced a deterioration in the reciprocal of serum creatinine
against time in 2 years [61. Third, they failed to measure GFR.
Diets similar to the ones they used are known to produce
muscle wasting. Without serial body weights or 24-hour urine
creatinine measurements, it is unclear whether the minimally
elevated or unchanged serum creatinine values truly reflected a
stable GFR. Fourth, the dietary protein was also reduced from
70 to 42 glday; simultaneously, dietary calcium was increased to
1.25 glday, Two years later [7], this same group reported similar
improvements in 78 patients treated for an average of 42 months
with a phosphate-restricted and protein-restricted diet com-
pared with 22 retrospective controls on a free diet followed for
24 months. Although the hypertensive and nephrotic patients
experienced faster renal functional decline than did patients
with either polycystic kidney disease or chronic pyelonephritis,
these concerns still apply.
About the same time, Barsotti et al tried to retard progressive
renal failure by using a diet low in phosphorus (475 versus 850
mg/day) and nitrogen (39 versus 56 g protein/day). Over the 11
and 21 months of studies respectively in one group of 20 and
another group of 29 patients with moderate renal insufficiency
[8, 9], urinary phosphorus was reduced (324 versus 650 mg/day)
in the first group. Endogenous creatinine clearance showed
either no change in the shorter study (versus 5 mI/mm fall per
year in the pre-experimental-diet control period) [8] or a small
decline in the longer study (1.7 versus 6.6 mllmin per month in
the pre-diet control period) [9]. The fall in creatinine clearance
directly correlated with 24-hour urinary phosphorus but not
with urinary urea, implicating a closer relationship with dietary
phosphorus (Fig. 1). In 1986, the same authors reported that a
similar dietary approach, that is, a 500 mg phosphorus and 35 g
protein diet supplemented by 1.2 g calcium, yielded stable
creatinine clearance and body weight for 12 months in 85
patients with a mean creatinine clearance of 9.5 mI/mm [10].
Besides being brief in duration, it is impossible to know how
many of the original 49 patients, if any, were included in this
later study. The major problem with these studies is the lack of
prospectively randomized contemporaneous controls with iden-
tical characteristics and followup protocol.
Three other studies, involving 7, 10, and 4 patients and lasting
only 3,4, and 6 months respectively [11—13], also suggested that
a diet reduced to 35% to 50% of "normal" phosphorus and
protein intake stabilizes serum creatinine [12] and creatinine
clearance [11, 13] in patients with moderate-to-advanced renal
insufficiency. These studies suffer from the same problems,
however: inappropriate controls, brevity, lack of GFR data,
and failure to exclude other nutrients as confounding variables.
For example, 5 years after the original publication, Tessitore et
al reported a decline in iodothalamate clearance from 44 to 12
mI/mm in 6 other patients treated with a similarly low (700 mg)
phosphorus diet for 29 months [14].
Could we tease out the role of a low phosphorus intake by
examining the effects of a low-protein diet per se? Unfortu-
nately, similar reservations also apply to studies on protein
restriction (Table 2). For example, although Barsotti et al
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Fig. 1. The change in creatinine clearance (negative signs indicating a
fall) was not correlated with 24-hour mean urine urea (uU) excretion
(A), but with mean urine phosphorus (uPi) excretion during periods of
control diets (B). (From Ref. 9.)
attributed the slower decline in creatinine clearance over 10
months in 12 patients to a low-protein diet, we face the same
problem in assessing this result. In particular, the simultaneous
reduction in dietary phosphorus (from 600 to 300 mg/day) and
increase in dietary calcium confounds interpretation of the
effect of a single variable [15].
This is also true in another study that compared a low-protein
diet in 31 patients with a mean serum creatinine over 6 mg/dl to
another 10 patients on an ad-libitum diet [16]. Although the rate
of increase in serum creatinine was slower over 2 to 3 years in
the treated patients, GFR was not measured. Such a study
leaves open the possibility that decreased creatinine produc-
tion, rather than a change in GFR, is responsible for the
stability in serum creatinine over time [12]. In addition, an
independent effect of dietary phosphorus restriction was not
excluded.
A Swedish study also showed that in 17 patients with a serum
creatinine of 10 mg/dl, treatment with an 18 g/day protein diet
for 1.5 years reduced the slope of the reciprocal of serum
creatinine against time [17]. Such studies in a smaller group and
lasting even a shorter time are open to identical criticisms:
without serial body weights and GFR data [17], changes in
serum creatinine might merely reflect muscle wasting and
falling creatinine production [18, 19]. Furthermore, the role of
reduced phosphorus intake (to 350 mg/day), enteric phosphate
binders, and more frequent physician visits (every 33 versus
every 55 days), which could affect blood presure control, could
not be dissociated.
Mitch and coworkers studied a 25 glday protein diet supple-
mented with essential amino acids (BAA) and ketoacid ana-
logues (KA) [20]. Although an improvement was evident in 60%
of the 17 patients who had a defined rate of decline during the
pre-diet period, serum creatinine deteriorated in 6 of the 7
patients without a defined rate of decline in the pre-diet period.
Again, the use of historic controls, the short duration of the
study, the limited creatinine clearance data (measured only in
one-third of the subjects), and the simultaneous reduction in
dietary phosphorus (600 mg/day) preclude conclusions about
the separate effects of the individual dietary manipulations.
A British group treated 39 patients with a 35 g/day protein
diet for 6 months and found an improvement in the slope of the
serum creatinine in 93% of the patients, with the best response
in those with tubulointerstitial diseases [21]. Unfortunately, this
study is vulnerable to the same four criticisms.
Finally, 3 other studies that report improvement in the
reciprocal of serum creatinine plotted against time were simi-
larly flawed by their failure to specifically eliminate the con-
founding variable of phosphate restriction [18, 19, 22]. Two of
these also employed historic data as the control [19, 22], had a
small sample size, and provided no [22] or uninterpretable data
on creatinine clearance (24-hour urine creatinine excretion fell
during treatment because of diminished muscle mass) [19]. One
study provided prospective, appropriately randomized controls
and compared 100 subjects on protein restriction with a similar
number on an ad-libitum diet [18]. Again, however, GFR was
not measured and the possible role of phosphorus restriction is
uncertain [18].
Can we learn more about the single role of protein restriction
from animal models of renal disease [23—28]? Several dozen
studies demonstrate and confirm a beneficial effect of dietary
protein restriction on renal pathology [23, 28], proteinuria [23,
25, 27, 28], BUN [18, 21, 23], serum creatinine [18, 22, 26, 27],
and survival [23, 24, 26, 27] (Table 3).
In one study of rats with nephrotoxic serum glomerulonephri-
tis, for example, a low-protein diet for 10.5 months improved
renal histology, decreased proteinuria, decreased BUN, and
decreased the number of deaths due to renal disease [23]. In a
model of immune glomerulonephritis, a low-protein diet for 6
months was also found to ameliorate the severity of the renal
lesion [24]. In rats subjected to eight-tenths nephrectomy, Ritz
et al found that the mortality rate due to uremia was decreased
by a lower protein intake [29]. In another study, the histopa-
thology, proteinuria, and number of renal-related deaths was
decreased by a protein-restricted diet in rats with five-sixths
nephrectomy [26]. In all these studies, the presence of other
nutrients cannot be factored out as confounding variables, and
the lack of data on GFR leaves the conclusions questionable.
Estimates of GFR were attempted in 3 experimental studies
that suggest a salutary effect of a low-protein diet on renal
disease [25, 27, 28]. Two showed no changes in GFR [25, 28]. In
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one, all the other nutrients were kept identical between the low-
and normal-protein diets, but the authors failed to quantify food
intake, leaving open the possibility that the improved renal
lesion and proteinuria were due to variations in intake of other
nutrients [25]. In the other study, treatment with a low-protein
diet for one month in rats with adriamycin-induced glomerulo-
nephritis was found to improve the renal lesion and proteinuria,
but not the inulin clearance [28].
To the best of my knowledge, only in the study by El-Nahas
et al was endogenous 24-hour creatinine clearance found to be
improved by 5.5 months of a low-protein diet in rats with
five-sixths nephrectomy [27]. Unfortunately, absolute food
intake, and therefore phosphorus intake, were not quantified
despite identical phosphorus content; thus one cannot exclude
the possibility that protein-restricted rats consumed less phos-
phorus because of anorexia. In addition, measurements as long
as 129 days after protein restriction revealed no differences in
serial serum creatinine. Although not specified in the text, I
surmise (from the data points on the graph depicting creatinine
clearances) that the creatinine clearance measurements were
made at 129 days [27]. To me, however, it is not clear how a
better creatinine clearance result could be obtained in rats fed a
low-protein diet when their serum creatinine (at 129 days) was
numerically higher and body weight numerically lower.
Such skepticism about the efficacy of protein restriction in
preserving renal function is warranted in view of evidence
suggesting that a chronic high-protein diet has a beneficial effect
on glomerular filtration rate [30—39] (Table 4). In sheep with
intact kidneys, a low-protein diet decreased GFR [30]. In rats
with one-half or three-fourths nephrectomy, Schoolwerth et al
showed that one week of a high-protein (40%) diet increased
inulin clearance by 29% and 38% [31]. In rats with more severe
renal ablation, Hostetter et al also found that a normal-protein
diet (24%) sustained a higher GFR than did a low-protein (6%)
diet [32]; this finding is one of the bases for the hyperfiltration
hypothesis [40—43]. Single nephron GER in residual nephrons of
a remnant kidney model is two- to threefold of the normal
unless dietary protein is reduced [32].
After 5 weeks, the increase in GFR produced by a high-
protein diet was sustained in normal animals and in animals
treated with adriamycin [34]. Even into the eighth week, the
beneficial effects of a higher protein diet on renal plasma flow
and GFR persisted in these animals [35]. Does the same
hemodynamic response occur in humans? One study, which
evaluated the effect of a 90 g protein diet for one week,
answered affirmatively [34]. In another study, 24 patients with
renal insufficiency responded to 4 weeks of protein supplemen-
tation with similar increments in GFR (58 mllmin versus 48
mi/mm) and effective renal plasma flow (240 mi/mm versus 205
mI/mm) [37].
It is appropriate, of course, to raise concern about the
possible adverse effects of hyperfiltration and glomerular hy-
pertension. These physiologic adjustments to a high protein
intake presumably lead to glomerular sclerosis and impaired
glomerular function. In adult dogs fed a high- or normal-protein
diet, the clearances of both paraaminohippuric acid (PAH) and
inulin were significantly higher than those in animals fed a
low-protein diet [38]. Even 4 years after three-fourths nephrec-
tomy, the effects of high-protein diets were sustained. In these
adult animals, neither histology on light microscopy nor ultra-
structure on electron microscopy differed among the 3 different
protein diets [38]. In the rat with either uninephrectomy or
five-sixths nephrectomy, Hostetter et al also observed sus-
tained benefits on GFR after 8 months of treatment with a high-
versus a low-protein diet, despite heavier proteinuria and
increased glomerular sclerosis [39]. Considering the average
longevity of dogs and rats, these results cast doubt on the
prediction or implication that chronic glomerular hypertension
and hyperfiltration will eventually cause a progressive decline
in GFR.
Given the paucity of evidence from animal studies that
protein restriction per se improves GFR, and the substantial
data suggesting a salutary influence of a high-protein diet on
GFR, we can reasonably conclude that the effects of a low-
phosphorus diet on GFR are not mediated by the associated
protein restriction. Do we have more concrete evidence that
supports a role of phosphorus from animal studies? If excess
phosphorus is indeed nephrotoxic, a low-phosphorus diet should
ameliorate, and a high-phosphorus diet should aggravate, the
impairment of GFR. In addition, at a given dietary phosphorus
content, agents that reduce phosphorus absorption or inhibit
calcium phosphate precipitation should result in a higher GFR.
Let us examine the evidence (Table 5). In 1978, Ibels et al
found that a low-phosphorus diet (0.04 g% versus 0.5 g%),
initiated 6 weeks before and continued for 24 weeks after
seven-eighths nephrectomy in adult rats, sustains a better
serum creatinine with or without enteric phosphate binders
[Al(0H3)] [44]. This diet also reduces the serum calcium X
phosphorus product, ameliorates the histologic lesions, and
increases survival.
Two years later, using a model of antiglomerular-basement-
membrane glomerulonephritis, Karlinsky and colleagues not
only confirmed these results with a phosphorus-restricted diet
but also found that the calcium content in the kidney was
reduced compared with that from rats fed a normal-phosphorus
diet [45]. The reduced body weight in phosphorus-restricted
rats left uncertain whether the serum creatinine truly reflected
GFR. These two 6-month-long studies [44, 45] were corrobo-
rated, however, and extended by a similar experiment in rats
with nine-tenths nephrectomy [46]. In the latter study, a 0.03
g% phosphorus diet decreased the serum calcium x phosphorus
product, serum creatinine, incidence of end-stage renal disease
(9% versus 70%), tubular lesions, and deaths attributed to
uremia when compared with a normal-phosphorus diet [46].
Two studies in the rat subjected to five-sixths nephrectomy
failed to detect differences in serum creatinine [47, 48] or
creatinine clearance [47], but the negative results are likely due
to less stringent phosphorus restriction (20% to 24% of normal)
and a shorter evaluation period (3 to 4 weeks [47, 48]). These
studies, however, did confirm the attenuation of calcium and
phosphorus in renal tissue [48] and prolonged survival with a
lower phosphorus intake [47]. Thus, calcium and phosphorus
deposits might precede functional deterioration. In one of the
studies, survival rates improved with a low-protein diet, and the
beneficial effects of low-protein and low-phosphorus diets were
additive [47], although the number of animals studied was
small.
Thus, increasing evidence suggests that phosphorus restric-
tion exerts a salutary effect on renal damage and GFR. The next
question is whether dietary phosphorus loading potentiates
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Table 4. Improvement of giomerular filtration rate by chronic increase in dietary proteina
Ref. Model
Dietary
protein
Rx
time GFRl,C
Urinary
protein
Glomerular
histology
Food
intake Comments
30 Normal sheep 14 vs 2 wks per kg BW, NA NA ? Same No BW data(N= 19vs13) 5g% t31%
31 Rats with 3/4 Nx 40 vs I wk C 29% NA NA ? Same No BW data
(N=6vs6) 6g%
1/2 Nx 38%
(N = 6 vs 6)
32 Rats with 24 vs 2.5 C 24% NA Worse ? Same —
11/12 Nx 6 g% wks
(N = 9vs 11)
33 Adult dogs with 54 & 26 2 wks 21% (CPAH 25%) No A NA ? Same 6% BW A between
7/8 Nx vs 18 diets
(N=4) &8
g%
34 Rats with 35 vs 5 wks 75% C NA ? Same Slight C in BW
adriamycin- 20 g%
GN (N = 10
vs 15)
Normal rats C 45% C(N = 15 vs 15)
35 Rats with 5/6 Nx 25 vs 8 wks C 37% C Worse ? Same BP & BW no A(N=9vs8) 20g%
36 Normal 90 vs I wk C 18% NA NA ? Same ? Same diet(N=5) 70
g/day
37 30 men with 85 vs 4 wks C 16% (CPAH C C NA ? Same BP no A; BW C by
chronic renal 35 9% in 24 1 kg
disease g/day compliant pts)
38 Adult dogs 56 4 yrs C 29% & 33%; No A No A ? Same Uremic deaths not
with 3/4 Nx 27 vs (CPAH 1 32% correlated with(N = 10 and 5 19 g% & 51%) diet; BP, no A
vs 6)
39 Intact rat (4 mon) (8 mon) No A or C ? Same Diet P (0.86 vs 0.63
kidneys C 26% C 30% for 8 g%) & BW were(N = 9vs 12) mon ¶ by high-
with 1/2 Nx 40 vs 8 mon ¶ 35% ¶ 27% C No A or protein diet(N=9vs9) 6g%
with 5/6 Nx 1 33% 1 22% C C(N = 11 vs 11)
Nx, nephrectomy; GN, glomerulonephritis; PAH, para-aminohippurate; NA, not analyzed; BW, body weight.b GFR measured by clearance of inulin or iodothalamate;
C Changes expressed as % of value for normal-protein diet, either measured or interpolated.
renal injury. At least 3 groups have examined this issue; all survival of weanling rats at 20 weeks after seven-eighths
yielded a positive answer [49—52]. In 1979, Kleinknecht et al nephrectomy, if they were fed a diet high in protein, sodium,
reported a deterioration in serum creatinine at 4 weeks and in and phosphorus (1.58 g% in the experimental rats versus 0.98
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Table 5. Effects of low-P diet ion chemistry, histology, and survival in experimental renal diseasesa
Serum
Ref.
Rat
(model)
Diet P
(g%) Rx time
[Ca] x
[P1
Serum
creat
Urinary
protein Renal lesions Survival Comments
44 Adults with 0.04 Al(O}T)3 6 pre- & 39 vs 105 Better 7 to to 33% Better 75% vs zero No BW; no food
7/8 Nx vs 0.5 24 24 wks at 24 wks data
(N=12 wks
vs 26) post-
Nx
49 Weanlings 0.98 vs 1.58 20 wks NA Better at NA NA 70% vs 22% Diet NA &
with 7/8 post- 4 wks at 2 wks protein also
Nx (N Nx C food intake
10 vs 9)
45 Anti-GBM 0.14 vs 0.05 23 wks NA Better from No Better 70% vs 10% kidney Ca;
GN(N = Sto 13 at23wks LBW;nofood
11 vs 13) data
50 1/3 and 1/2 0.5 vs 1 and vs 2 18 wks NA at 18 NA Better; (C kidney NA Fed only 10 g/
Nx (N = wk; Ca & P04 with day; BW on
4 per [C Ccreat Nx & with 2 g% P diet; no
group per in 1/3 Nx diet P) in BP
diet) at 7 wkj
Intact on 3
g% P
EHDP vs none 5 wks NA ( s,,) No NA Better NA No i in Ccreat
51 Weanlings 0.75 vs 0.98 30 wks NA Better from NA Better 90% vs 10% No food data;
with 7/8 the 4th at 30 wks J, BW; . BP;
Nx (N = wk on diet protein,
llvsl3) Ca,&Na
52 7/10 Nx (N 0.58 vs 2.2 4 wks 75 vs 102 0.58 vs NA Tubular lesions & NA C Tissue CA &
= 5 vs 12 phosphocitrate vs 95 1.90 vs calcinosis; only BW on 2.2%
vs 15) 0.77 2.2% P diet P diet alone;
food data spotty
46 9/10 Nx (N 0.03 vs 0.2 vs 36 wks with Lower with NA Fewer tubular 80% vs 10% After 26 wks, no
= 11 vs 0.5 low-P 0.03% P lesions at 36 wks food data;
10 vs 10) diet diet BW &
ESRD (9 vs
70%) with LPD;
benefits partly
mimicked by
food intake
47 5/6 Nx (N
= 10 vs
0.12 vs 0.5 g 3 wks Na (.j si,) No
(Ccreat
NA NA C by LPD
only in
No food data; low
(6%) protein
11) also
similar)
very
uremic
rats
diet C survival
& , s
regardl'ess and
synergistic with
J, P diet
48 5/6 Nx (N 12 vs 63 mg P1 3 wks NA No NA NA NA kidney Ca & P;
=?) day no food or BWdata; no in
BP
53 5/6 Nx (N Normal P chow 14 wks 43 vs 127 at 12th . 80% by sclerosis 8 vs C by BP no
= 9 vs 9) DHAAA and 14th
wks
(C Cereat)
DHAAA 67%; DHAAAI tubulointerstitial to 67% vs
lesions 22%
I kidney Ca;
inulin clearance
in only 3 rats;
no food data
a Nx, nephrectomy; NA, not analyzed or not assessed; DHAAA, dihydroxaluminum aminoaceate; GBM, glomerular basement membrane;
EHDP, disodium ethane-l-hydroxy-l-l-diphosphonate; si,. serum phosphorus; LPD, low-protein diet.
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g% in the control rats) [49]. The followup study, in which the
authors used a smaller load of phosphorus (0.98 g% versus 0.75
g%), protein, and sodium, confirmed the adverse effect on
serum creatinine 4 weeks into the dietary treatment, on mor-
tality at 30 weeks, on renal pathology, and on hypertension [511.
Although no data were given on body weight and GFR, this
study illustrated the deleterious potential of excessive phospho-
rus and/or protein intake in renal failure.
At about the same time, Haut et al substantiated the nephro-
toxicity of a high-phosphorus diet (2.0 g% versus 0.5 g%) in rats
with prior one-third or one-half nephrectomy [50]. The endog-
enous creatinine clearance was lower in the one-third nephrec-
tomy model after 7 weeks of a high-phosphorus when compared
with the normal phosphorus diet. Both partial and complete
unilateral nephrectomies were associated with increased renal
calcium and phosphate deposits (Fig. 2), which were aggravated
by doubling or quadrupling dietary phosphorus in rats after
uninephrectomy [50] (Fig. 3). Calcification was most prominent
in tubular lumens near the corticomedullary junction, and some
calcium in the interstitium was thought to have been derived
from degenerated tubules. Severely affected tubules appeared
to have calcification of the epithelial cells [50]. The importance
of excessive dietary phosphorus alone (for example, 2.0 or 3.0
g% versus 0.5 g%, the level generally considered normal) was
underscored by the demonstration by Alfrey and coworkers
that after 5 weeks of such a diet, tubulointerstitial abnormali-
ties, renal calcification, and increased calcium and phosphorus
content developed even in rats without prior renal ablation [50].
Although creatinine clearance was not detectably worsened at 5
weeks, these authors suggested that functional deterioration in
previously healthy kidneys can be produced by dietary phos-
phorus loading, and that such deterioration is preceded by renal
parenchymal calcification [50]. The severity of the histologic
lesion and net kidney weight correlated positively with kidney
calcium concentrations. Renal phosphorus content rose in
association with renal calcium content; this finding suggests the
deposition of compounds composed of both calcium and phos-
phate [50]. Finally, these investigators found a direct correla-
tion between the severity of the histologic lesions for the intact
and uninephrectomized rats and the daily excreted load of
phosphate per nephron (assuming 30,000 nephrons per rat
0.5% diet 1.0% diet 2.0% diet
(Group 1C) (Group 2C) (Group 3C)
•Aorta * £
aK,dney
1 23456123456123456
Animal number
Fig. 3. Increasing dietary phosphorus from normal (0.5%) to 1% and 2%
was associated with increased Ca concentration in the aorta (solid
circles) and in the kidney (open triangles) harvested from rats previ-
ously subjected to uninephrectomy. (From Ref. 20.)
kidney) at 3 levels of dietary phosphorus (0.5, 1.0, and 2.0 g%)
[50] (Fig. 4).
The third line of evidence implicating phosphate nephrotox-
icity comes from four studies. First, enteric phosphate binders
are known to sustain a lower serum creatinine and to ameliorate
the renal lesions in rats with seven-eighths nephrectomy when
used with a low-phosphorus diet [44]. Concerns can be raised
regarding the anorexic effect of a low phosphorus diet, but a
followup study by Alfrey and colleagues partially resolved this
and the GFR issues [53]. Rats with five-sixths nephrectomy fed
chow containing the usual amount of phosphorus (normal-
phosphorus diet) received either dihydroxaluminum-aminoace-
tate (DHAAA) as a phosphate binder for 14 weeks (experimen-
tat group) or an equivalent quantity of glycine mixed with the
normal-phosphorus diet (control group) [53]. The DHAAA
raised serum calcium and lowered serum phosphorus, as ex-
pected, and led to a lower serum creatinine and higher endog-
enous creatinine clearance at 12 and 14 weeks of treatment.
This effect was assumed to reflect GFR because they found few
3.
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Fig. 2. Increasing nephron losses were
associated with increasing Ca concentration
and worsening histologic abnormalities in the
remnant kidneys harvested from rats
subjected to partial (1/3) nephrectomy and to
uninephrectomy and raised on 1% phosphorus
diet. (From Ref. 50.)
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Fig. 4. Correlation between estimated phosphate load excreted per
nephron based on a 24-hour urine collection at week 7 and the degree
of renal histologic abnormalities determined at the conclusion of the
study at week 18. Data points were derived from rats with intact kidneys
and with uninephrectomy that were fed a 0.5%, 1%, and 2% phosphorus
diet, assuming 30,000 nephrons per kidney. Rats with 1/3 nephrectomy
were excluded from this analysis because the exact number of residual
nephrons could not be estimated. (From Ref. 50.)
discrepancies between inulin clearance and creatinine clearance
measured concomitantly in 3 rats [53]. The incidence of glomer-
ulosclerosis and tubulointerstitial lesions and renal-tissue cal-
cium content were markedly reduced by DHAAA, as was the
mortality rate (33% versus 78%). As with their original study
[44], interpretation of this study remains ambiguous because
without data on food and protein intake, the reduction in
proteinuria by Al(OH)3 [44] or DHAAA [53] cannot be defini-
tively interpreted.
Gimenez et al evaluated the effect of 3-phosphocitrate, an
inhibitor of calcium phosphate precipitation and tissue calcifi-
cation, in a rat model with seven-tenths nephrectomy fed a high
phosphorus (2.2 g%) diet [52]. Compared with a normal-phos-
phorus (0.58 g%) diet, rats fed the high-phosphorus diet expe-
rienced a fourfold increase in serum creatinine levels after 4
weeks. These animals developed tubulointerstitial disease and
nephrocalcinosis, and more calcium accumulated in their renal
tissue compared with rats fed a normal-phosphorus diet (Fig. 5)
[52]. The concomitant administration of 3-phosphocitrate pre-
vented these abnormalities despite a comparably high phospho-
rus diet and a similar degree of initial ablation (Fig. 5).
Contrary to the studies in which enteric phosphate binders
were used [44, 53], the calcium x phosphorus product was not
significantly reduced by 3-phosphocitrate. Thus, the beneficial
effects probably are mediated at the tissue level. A definitive
statement on improvement of GFR by this agent cannot be
made because the non-treated, phosphate-loaded rats might
have been volume contracted, as suggested by their decreased
body weight [52]. The emerging evidence argues strongly,
however, that in the remnant kidney model, a low-phosphorus
diet per se [44, 46, 49, 51] or agents that reduce phosphorus
absorption [44, 53] preserve renal function, as assessed by
serum creatinine [44—46, 51] or creatinine clearance [53], inde-
pendent of other nutrients [44, 531. The obverse, namely, that
excess dietary phosphorus is detrimental to residual renal
function, also is reasonably well supported [49—51]. Finally, the
adverse consequence of phosphorus loading on histologic ab-
normalities [50] and on serum creatinine [52] can be largely
blocked by diphosphonate [50] and by 3-phosphocitrate [52].
50 tzmoes
Phosphocitrate/d
FIg. 5. Renal Ca content (mmoles/IOO g wet weight of renal tissue) as a
function of dietary phosphorus and origin of the renal tissue. Cort. and
med. refer to cortical and medullary locations. Control diet contained
3.6 mmoles P/day as opposed to P04-fed rats that received 12 to 14
mmoles P/day. The latter exhibited a marked and highly significant
increase in both cortical and medullary Ca content in the kidney
remnant. In contrast, rats receiving increased phosphate intake plus
phosphocitrate (P. Cit) showed no significant increase in cortical Ca and
only a modest rise in medullary Ca, (From Ref. 52.)
Collectively, these 3 lines of data support a pathogenetic role of
phosphorus in progressive renal insufficiency.
How might excess phosphorus exert its deleterious effect?
The animal studies I have cited suggest that it does so by
precipitation in the kidney as calcium salts. From a pathophys-
iologic point of view, this hypothesis considers excess phos-
phate deleterious because: (1) Via a fall in ionized calcium, high
plasma phosphate levels raise parathyroid hormone (PTH), thus
increasing tubular fluid phosphorus (TF[P]) (Fig. 6) [57] and
elevating cytosolic-free calcium [54—56]. (2) Hyperphos-
phatemia (coupled with increased single-nephron GFR) in-
creases the single-nephron filtered load of phosphorus and
increases the absolute flux of phosphorus. (3) Hyperphos-
phatemia and a high PTH level potentiate the effects of each
other in raising TF[PJ and in predisposing to tubular CaPO4
precipitation.
Let us examine the scientific basis for the hypothesis that
excess phosphate is deleterious. In the remnant kidney, the
SNGFR is increased by 66% [57]. Although in this study serum
phosphorus was not increased, single-nephron filtered load of
phosphorus was more than double that of normal [57]. Frac-
r = 0.87
P<0.01
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Fig. 6. Tubular fluid-plasma 32P04 ratios (TF/
32P04) related to corresponding tubular fluid!
plasma inulin ratios (TF/P1) obtained from
micropuncture studies in 3 groups of rats
(normal rats with intact kidneys, rats with 2/3
nephrectomy, and normal rats infused with
inorganic P04). (From Ref. 57.)
tional reabsorption of phosphorus (FRP) fell, as confirmed in
uremic dogs by Wong et at [581 and by Wen and Stoll [591,
because of non-PTH-mediated [60, 611 and P1'H-mediated
inhibition of transport [62, 63]. The fall in FRP was slightly less
than one-half, so that absolute reabsorption of phosphorus
(ARP) by the proximal convoluted tubule up to the latest
accessible micropuncture sites (TF/plasma inulin of 2.5) still
increased. Clearly this increase in ARP is a function of the
magnitude of rise in SNGFR, which depends in part on dietary
protein intake [39] among other factors. In this scenario,
transepithelial flux of phosphorus across the proximal convo-
luted tubule increases. Similar reasoning probably holds true
for transepithelial flux of calcium and traffic through the renal
tubular cytosol. Cytosolic free calcium in proximal tubule [54,
56] as well as in distal nephron segments, like that in the
connecting tubule [55], is increased by PTH both acutely [54]
and chronically [561. The TF[P] also increases markedly in the
late proximal convoluted tubule [57] (Fig. 6). The increased TF
[Ca] x [P1 product leads to lumen calcification. The increased
transepithelial calcium and phosphorus fluxes increase the risk
of the renal tubules to calcium intoxication. The peritubular
capillary and the interstitium in turn are rendered more vulner-
able to the deposition of calcium and phosphorus. In essence,
the entire nephron and its immediate surrounding structures
become more susceptible to calcification.
Phosphate handling by the pars recta and the very early distal
tubule is altered similarly and adversely. Increased SNGFR, via
increased single-nephron filtered load, increases ARP several-
fold and raises TF[P] in the early distal tubule (Fig. 6) [57]
because of the inhibitory action of PTH and the intrinsic
diminution in tubular phosphate transport [63]. Phosphate in the
tubular fluid coursing through the distal tubule undergoes a
further increase; the ARP continues to be higher than normal.
In brief, both the tubular lumen phosphorus and the transepi-
thelial phosphate traffic increase. Using calcium-sensitive fluo-
rescent dye, we obtained preliminary results suggesting that in
the proximal tubule, cytosolic free calcium increases after
uninephrectomy [64]. Further, this abnormality can be partially
corrected by a low-phosphorus diet.
The TF[P] level at which calcium phosphate crystals are
likely to precipitate is unknown because many other factors,
including tubular fluid concentrations of other ions and crystal
growth inhibitors, levels of sulfate and oxalate [65], flow rate,
and pH also must be involved. Despite the paucity of in-vivo
information, we can estimate the critical concentration range.
In normal blood, one can derive crude [Ca] x [P1 product as
38 mgIdl2, or 3.1 mM2. Knowing that plasma ultrafilterable
calcium is about 60% of the total, we can approximate better by
using the product 1.9 mM2.
As an example, let us consider a patient with chronic renal
failure who does not take phosphate binders. Let us assume a
serum phosphorus of 12 mg/dl and a serum ultraffiterable
calcium concentration of 8 mg/dl. The calculated [Ca] x [P]
product is thus 96 mg/dl2, or 5 mM2 using the ultrafilterable
calcium. This figure would persuade most nephrologists to start
aggressive treatment. Micropuncture studies indicate a value of
1.5 mM for the TF[Ca] in the surface proximal tubule [66—691,
3.1 mM in the hairpin turn of the juxtamedullary nephron [66,
67], and 0.4 to 0.8 mM in the surface distal tubule [68—70].
Division of 5 mM2 by these TF[Ca] data yields an estimate for
the critical TF[P] at risk for precipitation: 3.3 mM for the
proximal convoluted tubule (a concentration attained in the
uremic rats studied by Bank et al [57]), 1.6 mM in the hairpin
turn; and between 6 and 17 mM respectively in the early and
late portions of the distal tubule. Micropuncture studies in
Munich-Wistar rats from portions of the accessible 1oop of
Henle [66, 71—75] suggest that the critical phosphorus concen-
tration of 1.6 mM is reached during infusion with phosphate,
PTH, or both [57, 68, 69, 71, 73, 75—77]. It is reasonable to
expect that in renal insufficiency this threshold can be exceeded
because serum PTH and phosphorus are only expected to
increase. Dietary phosphate restriction predictably reduces
TF[P] [74], theoretically offsetting these effects of renal failure.
The possible pathophysiology of phosphate nephrotoxicity is
schematically depicted in Figure 7. Besides other changes not
relevant to our discussion today, renal failure results in hydro-
gen and phosphate retention and in an adaptive increase in
SNGFR. Metabolic acidosis reduces citrate production and
increases citrate reabsorption [78, 79], reducing TF[citrate] in
the proximal tubule. Simultaneously, hyperphosphatemia and
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Fig. 7. Theoretical schema of the
calcjfication-precipi:ation hypothesis,
outlining the pathophysiology of phosphate
nephrotoxicity. ECF and ICF refer to
extracellular and intracellular fluids
respectively. SNOFR, single-nephron
glomerular filtration rate; SNFL, single-
nephron filtered load; vertical arrows within
boxes indicate increase or decrease as
directed; solid lines ending in an arrow
connecting boxes indicate a process or change
leading to another alteration.
hyperparathyroidism raise TFIPI, as I explained earlier [57, 70,
77]. The decreased TF[citrate] and increased TF[P] favor
precipitation of calcium phosphate in the lumen [781. The
medullary location of Henle's loop is particularly vulnerable,
given the higher TF[pH], the normally rising TF[Ca] [66, 67],
and TF[P] [66] as tubular fluid descends from the cortex toward
the papillary tip. By reducing ionized calcium [791 and
l,25(OH)2D synthesis, phosphate retention indirectly increases
PTH synthesis [801 and secretion, which in turn elevate cyto-
solic free calcium [54—56]. Coupled with the increased transcel-
lular calcium and phosphorus traffic and decreased citrate
availability, these changes increase the risk of cellular calcium
intoxication.
As I mentioned, the increased SNGFR raises the mass fluxes
of calcium and phosphorus through the cytosol and into the
interstitial space and capillary lumen. Exposure to increased
loads and/or concentrations of calcium and phosphorus in the
tubular lumen, cytosol, and the interstitium leads to tubular
calcification, atrophy, dilation, fibrosis, interstitial inflamma-
tion, and nephrocalcinosis as were found in experimental renal
diseases [44, 45, 50, 52, 53].
If this pathophysiologic schema is correct, a low protein
intake might exert its benefits by attenuating the rise in
SNGFR. Judicious alkali therapy might sustain a better TF[ci-
trate], as it presumably does as the basis for the effective
management of nephrolithiasis and nephrocalcinosis of familial
distal renal tubular acidosis. Finally, the restriction of phos-
phate intake or phosphate absorption is key to interrupting the
course and multitude of adverse metabolic consequences out-
lined here (Fig. 7).
Vitamin D metabolites also play a role. Serum I ,25(OH)2D
not only is directly related to GFR but also inversely related to
24-hour urinary phosphorus excretion, which reflects phospho-
rus intake [14]. In children with moderate renal insufficiency,
Portale et al found that 5 days of phosphate restriction plus
administration of Al(OH)3 or supplementation of dietary phos-
phorus produced the expected rise and fall, respectively, in
serum l,25(OH)2D. Serum PTH changed inversely as expected
[81]. These findings are consistent with the concept that in-
creases in 1 ,25(OH)2D3 within the physiologic range downreg-
ulate the synthesis and release of PTH.
Is it feasible to reduce the phosphate burden without resort-
ing to aluminum-containing entenc binders? I believe so. The
steps worthy of trying are: (1) Repeated patient education and
reinforcement. (2) Modest, not extreme, dietary phosphate
restriction (for example, allowing 70% to 80% of whatever one
was consuming before). (3) Administration of calcium-con-
taining enteric phosphate binders until serum calcium exceeds
11.5 mg/dl and/or urinary calcium exceeds 275 mg/day. When-
ever possible, one should encourage a copious fluid intake
compatible with the patient's ability to excrete water. Water
diuresis increases tubular fluid flow rate, decreases TF[Ca] and
TF[P] in the medulla, offsets the known hypercalciuric side
effect of phosphate deprivation [69], and ameliorates the con-
stipating effect of most phosphate binders. (4) Addition of small
doses of Mg(OH)2 as adjuncts and/or laxatives. Of course,
patients should be instructed to withhold these agents if oliguria
ensues.
The end point should be the lowest possible 24-hour urinary
phosphorus achievable; a rough rule of thumb is to achieve a
phosphate excretion 7 times the clearance of creatinine, with
the former expressed in milligrams and the latter expressed in
milliliters per minute. Since our demonstration in rats that
pharmacologic amounts of calcium carbonate virtually elimi-
nate intestinal phosphorus absorption [82], a number of clinical
trials [83—87] have emerged confirming the efficacy of calcium
carbonate in suppressing PTH [85] and in lowering serum
phosphate [83]. Recently, Sheikh et al reported that phosphate-
binding potencies are dependent on pH [87]. Calcium carbonate
is most effective at a pH of 5; the percentage of binding is time
dependent, whereas aluminum carbonate [Al2(CO] is rela-
tively insensitive to pH and to contact time [87]. Calcium citrate
tSNGFR in
residual nephrons
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is not as effective as calcium carbonate. Interestingly, calcium
acetate is more effective in the alkaline pH range, and its
phosphate binding potency is almost as great after 1 hour as
after 4 or 10 hours [87]. In 10 normal humans given a meal
containing 345 mg of phosphorus, calcium carbonate and cal-
cium citrate reduced net phosphorus absorption from 76% to
44% and 50%, respectively. Calcium acetate, however, was
found to produce the efficacy approaching that of A12(C03)3
(26% versus 18% of net phosphorus absorption). Net calcium
absorption was also lowest with calcium acetate. These results
with calcium acetate are encouraging, because the avoidance of
aluminum toxicity by using calcium-containing binders depends
on an effective substitute that doesn't carry the risk of produc-
ing significant hypercalcemia.
Guillot et al reported a modest reduction in serum phospho-
rus with Mg(OH)2 (0.75 to 3 glday) in uremic patients on
maintenance hemodialysis [84]. The serum phosphorus fell by
approximately 1 mg!dl compared with 2 mg/dl by Al(OH)3 alone
(in doses of 1.5 to 3.8 g), whereas serum magnesium rose by
approximately 1.4 mg/dl. Had they used a dialysate with a
magnesium level less than or equal to 1 mEq/liter, it might have
been possible to administer a larger amount of Mg(OH)2 with-
out producing significant hypermagnesemia [84].
In summary, I have proposed the precipitation-calcification
hypothesis of phosphate nephrotoxicity and reviewed the avail-
able but inconclusive evidence. I also have outlined the ratio-
nale and feasibility of reducing the total-body and renal phos-
phate burden by shunting the excretion of phosphorus from the
kidney to the lower intestine. Finally, I have raised the notion
that phosphate and protein are nephrotoxic via different mech-
anisms; hence they carry the potential for different but syner-
gistic therapeutic interventions [47]. Many issues remain. When
is the optimal time to begin reducing phosphate stores? How
severely should dietary phosphate be restricted? What is the
utility of hypophosphaturia as an end point? What is the role of
phosphate overload in initiating or sustaining various "idio-
pathic" tubulointerstitial disorders, and what is the precise
interrelationship, if any, between nephrotoxicity of phosphate
and protein? Clinical nephrology has entered a new and exciting
era of interventional therapy, and these questions should pro-
vide additional impetus for further research.
Questions and answers
DR. NICOLAOS E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): It is
my impression that the diffuse renal calcification observed in
uremic rats fed a normal diet in the study by Ibels and
colleagues [44] is at substantial disparity with the reported
histology in the rat remnant kidney model using normal diet.
The variance raises some concern about the applicability if the
dietary phosphorus hypothesis is accounting for the progressive
nature of renal disease.
DR. LAU: I am not sure whether there is really any disparity
in renal histopathology between what Ibels and colleagues
observed with a normal-phosphorus (0.5 g%), normal-protein
(24 g%) diet on the one hand [44], and what Hostetter, Brenner,
and coworkers observed with a normal-phosphorus (0.63 to
0.86g%) [39], normal-protein (24 g%) diet [32] on the other. The
apparent disparity merely might reflect a difference in emphasis
between studies directed at different objectives. For example,
Ibels et al did describe "glomerular fibrosis," although those
two words were "buried" by the detailed description of the
tubulointerstitial abnormalities, in particular renal calcification
[44]. As best can be surmised from the methods section and
supported by the results section, they did not plan to dwell on
the glomerular pathology [44]. In contrast, Brenner, Hostetter,
et al designed their experiments to concentrate heavily on the
glomeruli. They examined 200 to 600 glomeruli per rat, but they
made no mention of using special stains such as Von Kossa
stain, Alizarin-red stain, or Bunting stain for calcium and
phosphate minerals on light microscopy [32, 39]. Less than 5%
of their pathologic description was spent on the tubules and
interstitium. Rare "Ca deposits," "tubular atrophy and inter-
stitial fibrosis" were found, especially in areas where "glomer-
ular abnormalities were most prominent." Had these two
groups devoted equal effort and time on the other structures not
evaluated or elaborated, they might have documented similar
findings. Such an explanation is supported in part by the
description in a later study of glomerular sclerosis in 57% of rats
subjected to five-sixths nephrectomy and fed rat chow contain-
ing a normal protein and phosphorus content [53].
The applicability of the hypothesis of phosphate nephrotox-
icity in progressive renal disease still holds, in my opinion, not
only because of the functional evidence, but also because of
pathologic findings elicited by a high-phosphorus diet in normal
rats with intact kidneys [50, 88, 89]. Although no renal function
data were obtained, the serial pathologic studies by MacKay
and Oliver clearly demonstrated that a 2 g% phosphorus diet for
15 to 44 days in weanling rats without prior nephron losses
produced predominantly a tubulointerstitial lesion, localized
primarily in the outer stripe of the outer medullary zone and
characterized by necrosis of the terminal portion of proximal
convoluted tubules, regeneration of atypical epithelium, and
calcification of the necrotic debris that filled the tubules [89].
The glomeruli on light microscopy were well preserved [89]. In
a shorter-term study in 115 g rats, Craig reported similar tubular
pathology but also documented intraluminal calcium deposits in
the terminal proximal tubules and in the ascending thick limbs
of Henle's loop, as early as 3 to 6 days of exposure to a 2.2 g%
phosphorus diet [88]. These lesions were confirmed by Haut et
al, who fed normal intact rats a 3 g% phosphorus diet and
produced increased calcium accumulation in the renal tissue
[50]. Quantitatively, renal tissue calcium increased 10- to 50-
fold after feeding normal rats with intact kidneys a 3.2%
phosphorus diet respectively for 3 to 6 days; the effect was
sustained 6 weeks later [90]. Lumen calcification in the corti-
comedullary junction was similar to that found in nephrecto-
mized rats studied by Haut et al, who substantiated the asso-
ciated drop in creatinine clearance with a high-phosphorus diet
[50]. As I mentioned earlier, several groups have substantiated
a deterioration in serum creatinine with a high-phosphorus diet
or improvement with a low-phosphorus diet [46, 49, 50—52];
both changes were associated with corresponding changes in
tubulointerstitial pathology. Thus, I believe the literature is
persuasive regarding the phosphate nephrotoxicity hypothesis
and indeed supportive of its relevance in progressive renal
failure.
DR. JEROME P. KASSIRER (Associate Physician-in-Chief,
New England Medical Center): The idea that a single element
was responsible for progressive damage to the kidney is intrigu-
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ing, but one of our responsibilities is to be skeptical. How do we
know that the calcium deposition in the kidney is not simply an
epiphenomenon totally unrelated to the actual cause of the
declining renal function?
DR. LAU: Several lines of evidence argue against the notion
that the calcium deposition is a mere epiphenomenon. First, the
studies by Gimenez, Walker, et al showed that they could
revert or prevent the rise in serum creatinine in rats with
seven-tenths nephrectomy fed a 2.2g% phosphorus diet by the
concurrent administration of 3-phosphocitrate, a known inhib-
itor of calcium phosphorus crystallization [52] (Table 5). They
also showed parallel improvement in calcinosis and tubular
abnormalities and an attenuation in calcium content in renal
tissues in the rats treated with 3-phosphocitrate [521. These data
suggest that one can interrupt the pathophysiology, that is, the
functional deterioration, by preventing calcium phosphate dep-
osition in the kidney in spite of feeding a high-phosphorus diet.
The second line of evidence comes from the observation that
structural abnormalities (necrosis of proximal S3 [89], increased
calcium and phosphorus deposits in renal tissues [50], and
intraluminal mineral deposits [88]) can develop in intact kidneys
[50, 88] during consumption of a diet containing 2 to 3 g% of
phosphate [50, 88, 891. More significantly, these tubulointersti-
tial lesions (evident within days of a high-phosphorus diet [88,
89]), preceded demonstrable deterioration in serum creatinine
or creatinine clearance [501; this finding is consistent with,
although not necessarily supportive of, the notion that these
calcium-phosphate-induced lesions play a pathogenetic role in
the subsequent functional decline.
The third line of evidence can be drawn from the studies of
Haut et al, who used disphosphonate, a nonspecific crystal
growth inhibitor, admittedly with many other actions on min-
eral metabolism [50]. Diphosphonate administration prevented
the deposition of calcium-phosphate in renal tissue. In these
short-term (5-week) studies, the phosphate-loaded animals with
intact kidneys probably had not been exposed long enough to
raise serum creatinine. Thus, it was not possible to determine
whether diphosphonate exerts a salutary effect on creatinine
clearance.
DR. KASSIRER: I might have missed a point about the patients
on dialysis. You indicated that it would have been better to
eliminate magnesium from the dialysate, but shouldn't we be
paying attention to patients before they require dialysis? It is
these patients who are at risk of developing progressive renal
failure,
DR. LAU: I appreciate your question, which allows me to
clarify my comments. Of course we should focus more on
patients with mild to moderate renal insufficiency and explore
therapeutic measures to halt the progression to end-stage renal
disease. The ultimate objective of our present discussion is
precisely this. I proposed the phosphate nephrotoxicity hypoth-
esis to stimulate more research in pursuit of this objective. I
mentioned the clinical trial by Gennari et al in uremic patients
[84] because of the applicability of magnesium salts as adjunct
enteric phosphate binders (to the calcium salts) in pre-uremic
patients. If used judiciously, a bedtime dose of magnesium
hydroxide not only minimizes the constipating side effect of
calcium carbonate without incurring undue risk of hyper-
magnesemia in a nonoliguric patient, but it also adds to the
effects of the calcium salts. I didn't mean to suggest that
management of phosphorus overload in patients with end-stage
renal disease takes precedence over dealing with the same
problem in patients with mild to moderate and potentially
arrestable progressive renal disease. The top priority is to
prevent end-stage renal disease.
Let me make two other points: First, the same propensity to
accumulate excess phosphorus exists in pre-uremic and uremic
stages, hence the need to restrict phosphate in both periods.
More significantly, our current treatment in both instances still
largely depends on enteric phosphate binders [91], but compli-
ance unfortunately remains a common problem. Second, in the
case of dialysis patients, my earlier suggestion was that more
magnesium hydroxide (that is, more than the dose of 0.75 to 3.0
g!day used by Gennari et al) could be prescribed if a lower bath
magnesium concentration were used.
DR. PAUL KURTIN (Chief, Division of Pediatric Neplirology,
New England Medical Center): Is it possible to separate out the
effects of phosphorus from those of hyperparathyroidism? For
example, has a study been done comparing a low-phosphorus
diet with a normal-phosphorus diet in parathyroidectomized
animals?
DR. LAU: I am not aware of any study comparing a low- to a
normal-phosphorus diet in parathyroidectomized animals, in
exactly the way you suggested. It is an important issue because
some of the pathophysiologic consequences outlined in my
hypothesis (Fig. 7) are mediated by increased PTH (for exam-
ple, increased TF[P]), whereas others depend directly or indi-
rectly on phosphorus retention (for example, increased PTH,
increased TF[P], and increased single-nephron filtered load of
phosphorus). One important theoretical difference, however,
should be emphasized. Phosphorus restriction is known to
suppress PTH, thus ameliorating some of the adverse effects of
both hyperphosphatemia and secondary hyperparathyroidism.
In contrast, parathyroidectomy can be expected to aggravate
phosphorus retention.
I do know of two slightly different versions of the experiment
you mentioned. First, Borle and Clark measured renal calcium
metabolism by microfluorometric 40Ca and 45Ca kinetic analysis
in rats fed 6 to 8 times the normal dietary phosphorus (3.2 g%)
[901. They found that a high-phosphorus diet for as short as 3 to
6 days or as long as 6 weeks increased renal and mitrochondrial
calcium, cytosolic and mitochondrial exchangeable pools, and
all the calcium fluxes. Their quantitative data extended previ-
ous histochemical staining studies [88, 891, although none of
these 3 groups evaluated renal function to establish the adverse
impacts of a high-phosphorus diet, as some subsequent inves-
tigators did [49, 50, 521 (Table 5).
Borle and Clark next addressed the PTH question by feeding
a high-phosphorus diet to parathyroidectomized rats. Because
the changes in renal calcium metabolism appeared to be abol-
ished by parathyroidectomy, these authors suggested that
"nephrocalcinosis was caused by elevated PTH levels and not
by elevated plasma P04." But their failure to prevent profound
hypocalcemia (1.0 versus 2.0 to 2.5 mM) in phosphate-loaded,
parathyroidectomized rats left open the possibility that an effect
on tissue calcium, exerted by a high-phosphorus diet, might
have been obscured by the associated hypocalcemia. Accord-
ingly, these experiments didn't really differentiate the effects of
phosphate from those of hyperparathyroidism.
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The other study of relevance was done by Alfrey Ct al [92],
who found that in uninephrectomized rats with nephrotoxic
serum nephritis, thyroparathyroidectomy (TPTX) prevented
the progressive increase in serum creatinine observed in non-
TPTX rats (0.65 versus 3.8 mgldl at 23 weeks). Thyroparathy-
roidectomy also markedly attenuated the proteinuria, uremic
deaths, renal histologic damage, and calcification [92]. Mean
serum calcium in TPTX rats was kept normal at 9 mgldl by
thrice-weekly calcitriol injections. Since dietary phosphorus
was not reduced in either group and serum phosphorus levels
were similar (6.77 versus 6.71 mgldl in non-TPTX animals),
these authors concluded that "TPTX is equally effective in
preventing functional deterioration as P04 restriction" [92].
Unfortunately, these experiments were inconclusive. First,
without GFR measurement and details on weight gain and food
intake in both the 23-week and 7-week protocols, it is difficult to
be sure that the differences in creatinine in these two protocols
truly reflected changes in renal function. The second reserva-
tion arises from studies in which a weekly thyroxine replace-
ment dose was given to the TPTX rats; theoretically, the
differences between the TPTX and non-TPTX rats are simply
the absence of PTH and calcitonin. A third group of rats with
selective parathyroidectomy, studied by a pair-feeding schedule
in a 5-week protocol, actually had similarly low plasma creati-
nine (0.67 mg/dl) and creatinine clearance (0.397 mlIminIlOO g
body weight) as did the TPTX rats given levothyroxine [92];
these data support a pathogenetic role of PTH. On the other
hand, in a protocol lasting 7 weeks, but conducted without
pair-feeding or monitoring of food intake, these authors found a
lower plasma creatinine in TPTX rats given levothyroxine only
(0.9 mg/dl), but not in rats that had had parathyroidectomy (4.3
mg/dl), when compared with non-TPTX controls (4.8 mgldl).
Again, without GFR and/or serial body weights, these plasma
values might not be accurate indices of renal function. The
internal inconsistencies and these two reservations are reflected
by the authors' acknowledgment that the "mechanism of
TPTX's protective effect remains to be elucidated" [92].
DR. MADLAS: Vigorous phosphate depletion has the theoret-
ical potential for encouraging bone resorption. In fact, through
PTH-independent mechanisms, phosphate depletion can pose
limitations on titrable acid excretion that can, in turn, lead to
acid retention and further mobilization of bone buffer. Should
we be concerned about the potential for accentuation of renal
osteodystrophy by vigorous phosphate restriction?
DR. LAU: I think we should. But we also should recognize
two inherent features of phosphate restriction in renal failure,
especially in adults. First, in contrast to growing children or
young, growing rats, an adult not recovering from malnutrition,
starvation, or bone disease should be in zero phosphorus
balance. From day to day, an adult has the "problem" of
excreting between 700 and 1000 mg of phosphorus daily in the
urine. To maintain zero balance and avoid phosphorus intoxi-
cation, 60% [14] to 70% of the phosphorus intake, the amount
absorbed by the gut, must be eliminated. In renal insufficiency,
there is only a mild diminution in phosphorus absorption. The
residual nephrons must continue to eliminate almost the same
daily load of absorbed phosphorus, often at the expense of
producing secondary hyperparathyroidism and hyperphos-
phatemia. The problem therefore is the tendency toward exces-
sive retention. Patients with renal failure do not begin with a
normal phosphorus balance and hence are susceptible to phos-
phate depletion if they are phosphate restricted. Phosphate
restriction and/or entenc phosphate binders are measures that
only diminish the phosphorus burden and prevent increased
positive balance, not produce negative phosphorus balance.
Second, we must appreciate the fact that studies showing
increased bone resorption or osteomalacia by phosphate deple-
tion were by and large performed in young animals, which
require positive phosphorus balance for healthy growth. In
adult humans, osteomalacia develops because these patients
lose more phosphorus in either the urine or stool than they
absorb. Except for renal phosphate wastage seen in vitamin
D-resistant rickets, renal adaptation defends against negative
phosphorus balance produced by gastrointestinal losses. Their
problem is not excessive phosphate retention or increased
phosphorus balance, as is almost always inevitable in renal
insufficiency, but rather inadequate retention, or negative phos-
phorus balance. *
DR. KA55IRER: Let me ask you another question. There is a
phenomenon in animals called nutritional hyperparathyroidism.
If horses, for example, are given feed that is extremely high in
phosphate, they develop hyperphosphatemia, hypocalcemia,
and secondary hyperparathyroidism sufficiently severe to de-
calcify and deform their bones. Do such animals with severe,
sustained hyperphosphatemia and secondary hyperparathryoid-
ism develop progressive renal failure? If not, why not?
DR. LAU: The answer is probably yes, even though I can't
cite you any studies on horses. The rat experiments by MacKay
and Oliver showed that after 44 days of a high phosphorus
intake (2 g%), previously untouched normal kidneys in these
young rats were severely and irreparably damaged [89]. They
did not measure GFR, but I suspect that if measured, it would
be abnormal. Similar morphologic studies by Craig [88] and
renal tissue calcium analyses by Bone and Clark [90] reinforced
these findings.
DR. KASSIRER: Do you think that the acute renal failure that
occurs during rapid phosphate infusion is the consequence of
calcium phosphate deposition?
DR. LAU: My bias is yes, but in the few cases reported [93,
94], serum calcium fell from hypercalcemic to hypocalcemic
levels and was associated with variable degrees of hypotension.
Thus the acute renal failure might be hemodynamically medi-
ated as well. At postmortem examination, interstitial calcifica-
tion was found in the kidneys of these patients, but again, it
could not be unequivocally established that the ectopic calcifi-
cation was due to phosphate infusion rather than to pre-existing
hypercalcemia [93, 94].
DR. MADAI0: At what level of renal function do you initiate
therapy to lower serum phosphate? What precisely is the
therapeutic approach, and how do you monitor the patient's
response?
DR. LAU: I think the time to initiate therapy is a function of
two equally important variables, the residual GFR and the
amount of dietary phosphorus. The latter can be estimated by
the 24-hour urinary phosphorus level at a relatively steady state
on a self-selected diet. Under this condition, phosphate intake
is roughly 1.5 times the 24-hour urinary phosphorus excretion
[14]. If the 24-hour urinary phosphorus exceeds 800 or 900 mg,
I would contemplate enteric phosphate binders and/or advise a
modest reduction in dietary phosphorus, even with mild renal
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insufficiency, for instance, a serum creatinine of 1.3 mgIdl. My
prejudice is to prophylactically relieve the body—and the
kidney—of any phosphate burden at the first sign that the intake
is disproportionately high for the residual GFR. My rule of
thumb is to limit 24-hour urinary phosphate excretion (in mg) to
less than 7 times the creatinine clearance (in mI/mm). Even
when the GFR falls only slightly (for example, to 80 mI/mm or
80% of the maximum), I believe that it behooves us to institute
measures to proportionately ease the phosphate burden on the
remaining nephron mass, say, by restricting urinary phosphorus
excretion to 80% of the normal, or 560 mg/day. Analogous to
the reversal of hyperparathyroidism by dietary phosphorus
restriction in uremic dogs [95], I believe the regulation of
urinary phosphorus should be achieved at each and every
decrement in GFR. In patients with serum creatinines over 2.0
to 2.5 mgldl, we should aim to reduce the urinary phosphorus to
below 200 mg/day; the rationale for this is derived from the
animal studies by Ibels et al [44]. Extrapolating from the
relatively long duration of stabilized serum creatinine levels
produced by phosphate binders and phosphate restriction (168
days in a rat's life), I believe that we should strive towards the
lowest attainable urinary phosphorus excretion rate, as long as
significant hypercalcemia ( 11.5 mg/dl) and/or hypercalciuria
( 275 mg/day) are absent.
In brief, if GFR is 100 mI/mm, it is desirable to reduce urinary
phosphorus to 700 mg/day. If GFR falls to 50 ml/min, urinary
phosphorus should be lowered to less than 350 mg/day. I hope
these guidelines are practical enough to be followed easily.
DR. MADIAS: Harris et al have reported that chronic admin-
istration of the calcium-channel blocker verapamil provides
substantial protection from progression of chronic renal failure
in the rat remnant kidney model independent of any effect on
systemic blood pressure [96]. Do you have any insight about
how this benefit might obtain, especially given the current view
that the dominant hemodynamic effect of calcium blockers on
the kidney is to dilate the afferent arteriole?
DR. LAU: Thank you for bringing to our attention this
interesting study [96]. In this report, Harris and colleagues
extended an early investigation on the chronic effects of vera-
pamil from 3 [97] to 15 weeks in rats with five-sixths nephrec-
tomy and fed a normal-phosphorus diet [96]. Not only did these
authors confirm the significant amelioration in nephrocalcinosis
and tubular damage first reported by Goligorsky et al with
chronic verapamil therapy [97], but they also showed that at
sacrifice, 12 weeks into treatment, serum creatinine (2.29 mg/dl
versus 2.99 mg/dI), creatinine clearance (318 1.dlmin versus 164
pilmin) and mortality rates also were improved by the calcium-
channel blocker [96]. These renal functional and morphologic
benefits could not be attributed to mean arterial blood pressure,
which was not measurably altered by verapamil, as assessed
from 10 to 330 minutes after the previous dose [96].
I can't offer any insights on the mechanism of protection
other than emphasizing some of the comments by these inves-
tigators. The role of increased cellular calcium uptake is attract-
ive, because it can cause cellular damage by overloading the
mitochondria with calcium, induce plasma membrane injury by
activating phospholipases, and/or increase oxygen radical for-
mation. Although experiments in cultured rabbit proximal and
collecting tubules were cited as evidence for protection against
anoxic cell injury [961, alterations in intrarenal hemodynamics
(not detectable by systemic arterial pressure monitoring), as
you suggested, are equally reasonable mediators of the protec-
tive action. The existence of calcium channels in vascular
smooth muscle of renal microcirculation is better established
than renal epithelial cells per se. Presently, the specific target
element and the cellular mechanism of action are unclear to me.
I would, however, caution against optimism in this as a mode of
therapy, in view of the very modest benefit in serum creatinine,
the meager inulin clearance data, and the failure to detect
differences in survival after 12 weeks of verapamil treatment in
one protocol, despite demonstration of benefit after 7 weeks in
another protocol [96]. The results of both studies [95, 96] are
consistent with the hypothesis that calcium accumulation in
renal epithelium (reducible by calcium-channel blockers) and
nephrocalcinosis (preventable by 3-phosphocitrate [52] or phos-
phate restriction [44—46, 49—53]) play an important role in the
progression of renal failure.
DR. KURTIN: Children are known to have a higher range of
normal serum phosphorus compared with adults. What do you
think is going on in their tubules?
DR. LAU: Growth hormone has been postulated as the
mechanism because growth hormone appears to increase the
reabsorption of phosphorus [98] and contribute to the normally
higher serum phosphorus level in children. There are probably
other mechanisms or factors, but the complete picture is not
understood, at least not by me.
DR. KURTIN: Are children not at risk for this calcium-
phosphate precipitation?
DR. LAU: I don't think so. If the hypothesis I submitted to
you is correct, one would predict that the major risk factor is
increased TF[P] (Fig. 7). Growth hormone is expected to lower
proximal (and perhaps distal) tubule [P] and by increasing
reabsorption ultimately increase serum phosphate levels.
Viewed from this framework, the lower TF[P] in children, as in
young rats, should not pose increased risks to luminal calcium-
phosphate precipitation. Consider that children have to be
constantly laying down bone and constantly depending on
supersaturated concentrations of calcium and phosphorus in the
immediate microenvironment of the bone cell. It is teleologic, if
not physiologic, for children to have higher normal serum
phosphorus concentrations. If renal failure develops in a child,
however, the physician should manage the child using as a
guide the range appropriate for the age and gender of that child.
Please bear in mind the studies by Portale et al [81] showing that
serum phosphorus could actually be lower in children with
moderate renal failure than normal, despite hyperparathyroid-
ism and suppressed serum calcitriol levels, both of which are
biochemical evidence of excessive phosphate retention.
DR. KURTIN: The lower GFR of infants, corrected for surface
area, probably contributes to their slightly higher serum phos-
phorus concentration. Because of renal osteodystrophy, I think
it is important to keep the serum phosphorus concentration
normal in growing children. This is especially true now that we
and several other centers are using growth hormone in growth-
retarded children with renal disease. It is critical to keep the
milieu normal for bone formation. We would be concerned
about putting infants and young children on very low phospho-
rus diets because of the effects of that diet on bone formation
and growth.
DR. LAU: I completely agree with that. As in adults, in
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children with renal disease who are chronically receiving
growth hormone, I would definitely encourage the use of
24-hour urinary phosphorus levels, not only as a therapeutic
end point, but also as a monitor against excessive restriction of
dietary phosphorus or overdose with enteric phosphate binders.
Except for the disorders of vitamin D-resistant rickets charac-
terized by renal phosphorus wastage, phosphate depletion
resulting from dietary restriction (plus enteric phosphate bind-
ers) inevitably results in avid renal phosphate conservation. If
phosphate deficiency begins to develop, urinary phosphate will
become virtually zero [981. This is true if demand of a growing
child for phosphate exceeds the limited supply by the intestinal
tract. Let me reiterate some of the key features of the studies by
Portale et al in normophosphatemic children despite moderate
renal insufficiency [811. During periods of phosphate restriction,
as reflected by reduced urinary phosphorus excretion, serum
l,25(OH)2D3 levels responded by rising; conversely, during
dietary phosphate supplementation (as reflected by increased
urinary phosphorus excretion) serum l,25(OH)2D3 levels fell.
The secondary hyperparathyroidism also responded appropri-
ately in a reciprocal fashion. Because the phosphorus content in
the extracellular fluid, of which plasma is a fraction, is less than
0.1% of the total body phosphorus stores [99], physicians are
well advised to utilize and rely more on urinary phosphorus
excretion to evaluate whether a growing child, with or without
renal insufficiency, is getting too much or too little exogenous
phosphorus.
DR. KLEMENS MEYER (Fellow in Nephrology, New England
Medical Center): Apart from precipitation, how do increases in
cytosolic calcium or in calcium and phosphorus transit damage
tubular cells?
DR. LAU: Increases in cytosolic free-calcium concentration
to the micromolar range adversely affect cellular process such
as mitochondrial respiration and cause injury to plasma mem-
brane and other membrane intracellular organelles. For exam-
ple, the studies by Borle and Clark demonstrated increased
mitochondrial calcium and increased calcium fluxes across all
exchangeable pools of the kidney cells derived from phosphate-
loaded rats [90]. The studies by Goligorsky et al [971 and by
Harris and coworkers [96] emphasized structural damage and
calcium deposition as well as increased cellular calcium uptake,
which, earlier on, could be dissociable from tissue calcification
[48, 50]. Although controversial in terms of the precise relation-
ship, cell injury and death are closely linked to calcium over-
load. Very high intracellular calcium concentrations probably
exert multiple deleterious effects on the tubules as well. I
apologize if! gave the impression that calcium-phosphate could
actually deposit in the cytosol in the same manner that it
crystallizes in the tubular lumen. What I tried to suggest is that
the increased cytosolic "traffic" of calcium and phosphorus
(Fig. 7) perhaps is harmful to the cell. For instance, calcium
entry from across the basolateral membrane and from across
the apical membrane is stimulated by PTH [55], raising the
cytosolic free calcium in cells that have reduced citrate produc-
tion.
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